Health Economics›Rectal cancer›Neoadjuvant therapy

Neoadjuvant therapy

Rectal cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CapeOx, Cetuximab, RT Variant #01	—	R 125 772	35d	—	—	—	—	—
Capecitabine, Sorafenib, RT Variant #01	—	R 15 253	35d	—	—	—	—	—
Capecitabine and RT Variant #07	—	R 4 675	38d	—	—	—	—	1
FOLFIRINOX Variant #03	—	R 3 740	14d	—	~11.7 mo	—	—	3
CapIriRT Variant #01	—	R 3 185	35d	—	—	—	—	—
Fluorouracil and RT Variant #08	—	R 3 059	77d	—	—	—	—	2
FUOX and RT Variant #01	—	R 2 843	38d	—	—	—	—	1
mFOLFOX6 Variant #02	—	R 2 466	14d	~8.4 mo	~12.7 mo	~19	~R 46 863 PFS proxy · indirect	15
CapeOx, Camrelizumab, SCRT Variant #01 Partial	—	R 2 384	21d	—	—	—	—	—
CapeOx Variant #01	—	R 2 384	21d	~6.7 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	20
mFOLFOX6 and RT Variant #01	—	R 2 256	14d	—	—	—	—	—
FULV and RT Variant #07	—	R 1 616	70d	—	—	—	—	2
No neoadjuvant therapy Partial	—	—	—	—	~19.2 mo	—	—	8
Radiation therapy N/A - radiation Partial	—	—	49d	—	~9.2 mo	—	—	1

14 of 14 regimens shown